Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer
Climb Bio, Inc. (CLYM)
Company Research
Source: GlobeNewswire
WELLESLEY HILLS, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has strengthened its leadership team with the addition of Susan Altschuller, Ph.D., MBA, as Chief Financial Officer. Susan brings over two decades of strategic and financial leadership experience. “Susan is a seasoned biopharmaceutical leader with a strong track record in financial strategy, capital allocation, and operational execution, and we are delighted to welcome her to our team,” said Aoife Brennan, President and CEO of Climb Bio. “Our company is making excellent progress advancing budoprutug and CLYM116, and during the year ahead, we expect to generate meaningful clinical data from both programs that will guide our path forward. Susan’s financial and strategic expertise will be of tremendous value as we advance our pipeline and work to maximize the potential of our inves
Show less
Read more
Impact Snapshot
Event Time:
CLYM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLYM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLYM alerts
High impacting Climb Bio, Inc. news events
Weekly update
A roundup of the hottest topics
CLYM
News
- Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Climb Bio (NASDAQ:CLYM) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=CLYM&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</aMarketBeat
- Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswire
- Climb Bio to Present at Upcoming Investor ConferencesGlobeNewswire
CLYM
Earnings
- 3/25/25 - Beat
CLYM
Sec Filings
- 11/6/25 - Form 10-Q
- 11/6/25 - Form 8-K
- 10/17/25 - Form 8-K
- CLYM's page on the SEC website